Pfizer opens $200m clinical manufacturing plant in MA

Dan Stanton, Managing editor

May 15, 2019

1 Min Read
Pfizer opens $200m clinical manufacturing plant in MA
Pfizer's site in Andover, MA. Image: GoogleStreetview

The multiproduct facility will support early-phase manufacturing for its biologics pipeline, Pfizer says.

Last week, pharma giant Pfizer cut the ribbon on the latest addition to its biomanufacturing network in Andover, Massachusetts.

The Andover Clinical Manufacturing Facility (ACMF) represents an investment of $200 million (€178 million), which includes construction, additional processing equipment and qualification, according to Pfizer spokesperson Samantha Reardon.


Pfizer’s site in Andover, MA. Image: GoogleStreetview

“The multi-product facility is designed to deliver early phase clinical supplies for Pfizer’s extensive biological portfolio,” she told Bioprocess Insider. The firm boasts over 50 biologic and vaccine candidates in its pipeline.

“The facility provides a greater than 20% increase in capacity over the company’s current clinical facility.”

The plant has a modular and flexible design and houses five “discreet” production lines at 1,000 and 2,000 liter volumes, she added. It uses a mixture of single-use and stainless steel bioreactors.

Approximately 75 new jobs have ben created at Pfizer’s Andover campus, which also comprises of seven other buildings housing laboratories, clinical and commercial manufacturing suites, and support areas.

While Reardon said ACMF expands upon Pfizer’s internal biomanufacturing capabilities, it will not replace the use of contract development and manufacturing organizations (CDMOs).

“We will continue to utilize strategic clinical manufacturing partners as dictated by the specific demands of our portfolio.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like